NDA Submitted for Levadex for Migraine - ONA
Links shared publicly online about this topic.
- 262total visits
NDA Submitted for Levadex for Migraine - ONA
View full resource at oncologynurseadvisor.com
Tags: Migraine, Migraine Medication, Headache, Vascular Headache, Pharma, FDA, DHE 45, Migranal Nasal Spray
Most Recently Shared on May 27, 2011 at 2:01 pm By:
NDA Submitted for Levadex for Migraine http://goo.gl/fb/k7kM6
MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for Levadex
drugs.com — “Levadex (dihydroergotamine) is a new drug in development for the acute treatment of migraine. Levadex information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on August 2, 2011 at 11:08 pm By:
Drugs and Devices OW OW Health
MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for Levadex: MOUNTAIN VIEW, Calif., Aug. 2,... http://bit.ly/pR77XD #drug
MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX® - MarketWatch
marketwatch.com — “MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX® - MarketWatch” View full resource at marketwatch.com
Most Recently Shared on August 2, 2011 at 2:56 pm By:
John Carroll Health Communicator
Novo Nordisk is hiring and blueprinting a new US HQ in Jersey. http://bit.ly/nYdvlP
NDA Accepted for Levadex for Migraine - MPR
empr.com — “MAP Pharmaceuticals announced that the FDA has accepted its new drug application (NDA) of Levadex for the potential acute treatment of migraine in adults.” View full resource at empr.com
Most Recently Shared on August 2, 2011 at 2:00 pm By:
MPR News: NDA Accepted for Levadex for Migraine: MAP Pharmaceuticals announced that the FDA has accepted its new... http://bit.ly/oY8aXL
MAP Pharmaceuticals Submits New Drug Application to FDA for Levadex Orally Inhaled Migraine Drug
drugs.com — “Levadex (dihydroergotamine) is a new drug in development for the acute treatment of migraine. Levadex information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on June 1, 2011 at 12:10 am By:
Drugs and Devices OW OW Health
MAP Pharmaceuticals Submits New Drug Application to FDA for Levadex Orally Inhaled Migraine Drug: MOUNTAIN... http://bit.ly/kY3fZf #drug
NDA Submitted for Levadex for Migraine - MPR
empr.com — “MAP Pharmaceuticals announced that it has submitted a NDA to the FDA for Levadex (dihydroergotamine) for the potential acute treatment of migraine in adults.” View full resource at empr.com
Most Recently Shared on May 27, 2011 at 2:06 pm By:
MPR News: NDA Submitted for Levadex for Migraine: MAP Pharmaceuticals announced that it has submitted a NDA to t... http://bit.ly/miBPWb
MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults
news-medical.net — “MAP Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application to the United States Food and Drug Administration for LEVADEX orally inhaled migraine drug for the potential acute treatment of migraine in adults.” View full resource at news-medical.net
Most Recently Shared on May 27, 2011 at 5:38 am By:
MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults: MAP Pharmaceuticals, Inc. to... http://bit.ly/iwytro
NuPathe Submits Zelrix NDA for the Treatment of Migraine
marketwire.com — “NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that the company submitted a New Drug Application (NDA) for Zelrix™ to” View full resource at marketwire.com
Most Recently Shared on November 1, 2010 at 3:50 pm By:
NuPathe Submits Zelrix NDA for the Treatment of Migraine: Zelrix Poised to Be First Patch for Migraine http://bit.ly/a1pkUz
MAP Pharmaceuticals Announces FDA Will Not Require A Second Pivotal Efficacy Study For LEVADEX(TM) NDA Submission
medicalnewstoday.com — “MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's” View full resource at medicalnewstoday.com
Most Recently Shared on January 12, 2010 at 7:22 pm By:
MNT Clinical Trials Health News
MAP Pharmaceuticals Announces FDA Will Not Require A Second Pivotal Efficacy Study For LEVADEX(TM) NDA Submission http://mnt.to/3w9f
Second pivotal efficacy study not required for MAP Pharmaceuticals' LEVADEX NDA
news-medical.net — “MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study” View full resource at news-medical.net
Most Recently Shared on January 12, 2010 at 6:52 am By:
Second pivotal efficacy study not required for MAP Pharmaceuticals' LEVADEX NDA: MAP Pharmaceuticals, Inc. today a... http://bit.ly/5SILup
Advertisement
